Depletion of glioma stem cells by synergistic inhibition of mTOR and c-Myc with a biological camouflaged cascade brain-targeting nanosystem

Biomaterials. 2021 Jan:268:120564. doi: 10.1016/j.biomaterials.2020.120564. Epub 2020 Nov 24.

Abstract

Glioma stem cells (GSCs), as a subpopulation of stem cell-like cells, have been proposed to play a crucial role in the progression of drug-resistance in glioblastoma (GBM). Therefore, the targeted eradication of GSCs can serve as a promising therapeutic strategy for the reversal of drug-resistance in GBM. Herein, the effects of silencing c-Myc and m-TOR on primary GBM cells extracted from patients were investigated. Results confirmed that dual inhibition treatment significantly (p < 0.05) and synergistically suppressed GSCs, and consequently reversed TMZ-resistance when compared with the single treatment group. Subsequently, to facilitate effective crossing of the BBB, a biological camouflaged cascade brain-targeting nanosystem (PMRT) was created. The PMRT significantly inhibited tumor growth and extended the lifespan of orthotopic transplantation TMZ-resistant GBM-grafted mice. Our data demonstrated that PMRT could precisely facilitate drug release at the tumor site across the BBB. Simultaneously, c-Myc and m-TOR could serve as synergistic targets to eradicate the GSCs and reverse GBM resistance to TMZ.

Keywords: Biological camouflaged nanosystem; Cascade brain-targeting; Glioma stem cells; Inhibition of mTOR and c-Myc; Synergistic therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain
  • Brain Neoplasms* / drug therapy
  • Cell Line, Tumor
  • Glioblastoma* / drug therapy
  • Glioma* / drug therapy
  • Humans
  • Mice
  • Neoplastic Stem Cells
  • TOR Serine-Threonine Kinases

Substances

  • MTOR protein, human
  • TOR Serine-Threonine Kinases